XRTX Stock Analysis: Buy, Sell, or Hold?
XRTX - XORTX Therapeutics Inc. Common Stock
$2.18
0.00 (0.00%)
▲
5d:
-1.36%
30d:
-6.84%
90d:
+443.64%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When XRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XRTX shows positive signals but monitor for confirmation. Market pricing in 7.1% growth. Moderate conviction.
💡 BUY OPPORTUNITY: XRTX shows positive signals but monitor for confirmation. Market pricing in 7.1% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.47
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.53
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XRTX is currently trading at $2.18, which is considered slightly low relative to its 30-day fair value range of $2.16 to $2.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.0) compared to its historical average (1.6). At these levels, the market is pricing in 7.1% annual earnings growth.
Technical Outlook: Technically, XRTX is in a strong uptrend. Immediate support is located at $2.08, while resistance sits at $2.60.
Market Sentiment: XRTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.04 (+543.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XRTX is in a strong uptrend. Immediate support is located at $2.08, while resistance sits at $2.60.
Market Sentiment: XRTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.04 (+543.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.16 -
$2.50
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 543.8% below Wall St target ($14.04)
- BULLISH: Expecting earnings turnaround to 7.1% growth with None% revenue growth
Trading Range Analysis
30-Day Trading Range
$2.16 -
$2.50
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.09
Resistance Level
$2.60
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.98
Wall Street Target
$14.04
(+543.8%)
Earnings Growth (YoY)
-97.2%
Valuation Premium vs History
+7.1% premium
PE vs Historical
2.0 vs 1.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.1%
(market-implied from PE analysis)
1-Year Target
$2.33
(+7%)
2-Year Target
$2.50
(+15%)
3-Year Target
$2.68
(+23%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$2.16
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 15, 2026 5:40 AM ET
Data refreshes hourly during market hours. Next update: 6:40 AM
Data refreshes hourly during market hours. Next update: 6:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 66 BUY |
